Podcasts about biotech

A telecirurgia robótica representa um novo patamar para a saúde conectada no Brasil. Ao permitir que procedimentos de alta complexidade sejam realizados mesmo com médico e paciente separados por grandes distâncias, a tecnologia abre caminho para ampliar o acesso e reduzir desigualdades regionais no cuidado.No novo episódio do podcast de Biotech and Health, Camila Pepe e Carolina Abelin recebem Mirangela Machado, diretora-geral da MicroPort Brasil, para discutir a primeira telecirurgia robótica não experimental realizada no país. A conversa aborda os bastidores do procedimento, a infraestrutura de dados necessária, o papel da conectividade de alta velocidade e os desafios regulatórios envolvidos. Mais do que inovação tecnológica, o episódio mostra como a telecirurgia pode transformar a forma como cirurgias complexas são distribuídas em um país de dimensões continentais.

Welcome to this special Christmas Eve episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) hosted by Edge of Company with the Government Blockchain Association, this special captures live insights from industry leaders like Yat Siu, Brittany Keisser and Bill Foster on tokenization, blockchain policy, and decentralized ecosystems near the White House. Key TakeawaysYat Siu talks about how tokenization emerges as a transformative force, enabling network ownership, stablecoin expansion to unbanked populations, and AI agency through fixed blockchain rules. Bill Foster addresses permissioned blockchains, identity verification via mobile IDs, and stablecoin risks like bailouts. Brittany Kaiser champions data ownership, Telegram's TON blockchain for ethical social media, and privacy-preserving AI networksDiscussions explore how blockchain, AI, stablecoins, and data rights are reshaping finance, regulation, and global innovation.​We wish you a very Happy Holidays!! Support us through our Sponsors! ☕

Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the company has secured exclusive worldwide licensing rights to TNX-4900, a highly selective small-molecule Sigma-1 receptor (S1R) antagonist with demonstrated analgesic activity across multiple preclinical models of neuropathic pain. Lederman explained that Sigma-1 receptor antagonism has attracted growing scientific and clinical interest as a promising new class of non-opioid, non-addictive pain therapies. Tonix has leveraged computer-aided and artificial intelligence–driven drug design approaches to develop this next generation of selective S1R antagonists. TNX-4900 has demonstrated robust and durable pain-relief activity in several validated neuropathic pain models, alongside an encouraging preclinical safety profile. TNX-4900 emerged from a structure-based drug design program led by researchers at Rutgers University, which generated a series of potent and selective triazole-based Sigma-1 receptor antagonists. The compound binds to the human Sigma-1 receptor with nanomolar affinity (Ki = 7.5 nM), exhibits greater than 100-fold selectivity over the Sigma-2 receptor, and shows strong penetration of the blood–brain barrier. In addition, TNX-4900 demonstrates favorable pharmacokinetic characteristics, including attractive absorption, distribution, metabolism, and elimination (ADME) properties and an oral bioavailability of approximately 28%. These attributes support its potential suitability for chronic oral administration in pain indications. In preclinical models of both diabetic neuropathy and chemotherapy-induced neuropathic pain, TNX-4900 produced significant and sustained reductions in pain-related behaviours following both acute and repeated dosing. Importantly, these analgesic effects were observed without evidence of tolerance development or motor impairment, key limitations associated with many existing pain therapies. Tonix plans to advance TNX-4900 through expanded pharmacokinetic, formulation, and safety studies as part of an IND-enabling development program. According to Lederman, the company believes TNX-4900 represents a compelling opportunity to address a large unmet medical need with a differentiated, non-opioid therapeutic option for patients suffering from neuropathic pain. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #kidneydisease #massachusettsgeneralhospital #massgeneral #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #SethLederman #ChronicPain #TNX4900 #TONMYA #FibromyalgiaTreatment #NeuropathicPain #PostherpeticNeuralgia #FDAApproval #PharmaNews #ProactiveInvestors

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A Year of Biotech Bytes: Reflections, Stories, and Honest Moments#biotechbytes #biotechpodcast #behindthemicThis episode is a look back at the year, the lessons we learned, and the moments that shaped Biotech Bytes. Please visit our website to get more information: https://swangroup.net/I'm joined by Mary Louise Smith, the voice, support, and good energy behind every episode. She's the person many listeners never see, yet she's a major part of why this podcast runs the way it does. We talk about how Biotech Bytes really started, why simple conversations often lead to the best ideas, and how AI can help us focus on the work that matters most. Mary also shares what leadership looks like behind the scenes and a few personal stories that shaped our year, including our shared love for chocolate.If you've listened this year, thank you for being part of this community. Let us know what topics or guests you want to hear in the new year.Links from this episode:Get to know more about Bill Wallace: https://www.linkedin.com/in/williamwallace2Learn more about Intercept Pharmaceuticals:https://www.interceptpharma.com

  Pickelball & the Growth of Sports Enterprises & Investment w/ Evan Floersch of the Texas Ranchers Pickleball Team - AZ TRT S06 EP21 (283) 11-23-2025           What We Learned This Week: 1. Pickleball is now fully professionalized with a unified league structure. The merger of PPA + MLP created a stable, closed league system with real team economics, structured seasons, and national distribution. 2. Media partnerships are accelerating the sport's visibility. Pickleball now has a dedicated channel, plus national TV exposure on CBS and Fox—putting it in the same conversation as traditional sports. 3. Austin is becoming a major sports & tech hub fueling this growth. With Meta, Apple, Oracle, UT Austin, F1, MLS, and huge tourism, Austin is the perfect environment for emerging sports franchises. 4. Sports franchises are now a serious investment class—not a vanity asset. Private equity has poured $30B into sports recently. Firms like Permian aim to operate teams professionally, build value, and own multiple franchises across leagues. 5. The big opportunity is not just the sport—it's the stadium & real estate ecosystem. Sports districts (like The Battery or Wrigleyville) generate tens of millions by combining sports, entertainment, dining, hotels, concerts, and tourism. Pickleball could follow this playbook.         Guest: Evan Floersch– co owner Texas Ranchers   Evan Floersch is on a mission to redefine sports, starting with the 2 billion dollar professional pickleball industry as an entrepreneur, investor, and champion of change leading with a dynamic and forward-thinking passion. As the founder and CEO of the premier Texas Ranchers Major League Pickleball Team, he is transforming the industry while positioning Austin as a major sports hub integrating his passion for the city's thriving cultural arts and future tech scene.  In 2022, at just 26 years old, he made history as the youngest principal owner in sports by acquiring a controlling interest in the Texas Ranchers Major League Pickleball Team. Partnering with high-profile investors such as Lil Wayne, Scottie Scheffler, Kendra Scott, and NBA owner Dennis Wong, Evan is on a mission to turn the Ranchers into a global sports powerhouse. His long-term vision extends beyond pickleball—he has publicly committed the next phase of his career to elevating Austin, Texas, into one of the world's premier sports and entertainment markets. With its booming population, tech-driven economy, and untapped potential for championship-winning franchises, Evan sees Austin as the perfect city to build a lasting sports legacy.  A former All-American soccer player at Emory University, Evan's passion for competition and strategy extends to the pickleball court, where he plays regularly to better understand the game's evolution. While he grew up surrounded by Chicago sports, his true inspiration comes from those who have built or guided industry-defining companies, with books like Shoe Dog, The Innovator's Dilemma, The War of Art, and Relentless shaping his perspective on leadership, risk-taking, and disruption. Evan is an avid pickleball player and enjoys the fun and competitive aspect of America's fastest growing sport.  "Like great companies, a great sports organization isn't built by following the rules. It's built by questioning them, pushing past them, and creating something entirely new. The Texas Ranchers, and future sports franchises we helm in Texas, will win because we see beyond what sports are on the court or field."  - Evan Floersch, Founder and CEO         Texas Ranchers | Official Home of the Major League Pickleball Team  Texas Ranchers: A New Era of Sports Ownership & Global Fan Engagement   Who is the most valued high grossing sports franchise?  I bet you didn't guess professional pickleball did you? With pickleball exploding into a $2 billion industry and viewership surpassing major professional leagues, the Texas Ranchers are at the forefront of this revolution. By leveraging their brand authority and expansive network, they are attracting exceptional opportunities, captivating fans worldwide, and redefining what it means to be part of a professional sports franchise.   The Texas Ranchers Major League Pickleball Team is proving that ownership isn't just for high wealth individual ownership—it's a collective force driven by business leaders, entertainment icons, and sports enthusiasts. By bringing together a powerhouse network of investors—including Lil Wayne, Scottie Scheffler, Kendra Scott, and NBA owner Dennis Wong—the Ranchers are revolutionizing franchise ownership, making it more dynamic, engaging, and accessible.   The Texas Ranchers aren't just the most followed franchise in Major League Pickleball—they're the highest-grossing and one of the most marketable brands in the sport. With top-tier talent, including men's and women's pro players like Christian Alshon and Tina Pisnik, the team is fueling a movement that extends far beyond the court.   "We are creating something bigger than a sports team. The Texas Ranchers represent a global brand, powered by diverse leaders in sports, business, and entertainment. Our goal is to redefine sports ownership and elevate pickleball as a premier professional sport." – Evan Floersch, Co-Founder & CEO   The Texas Ranchers' Pillars for Success  The Texas Ranchers are built on a foundation of excellence, innovation, and inclusivity—three pillars that drive the team's success both on and off the court:   Democratizing Ownership – Unlike traditional sports teams, the Ranchers have created a model where ownership is a shared vision, uniting top minds from sports, business, and entertainment to amplify reach and influence.   Elevating the Sport – The Ranchers are committed to advancing pickleball into a premier professional sport, with top-tier athletes, world-class coaching, and high-performance training.   Building a Fan-First Experience – Through innovative media partnerships, interactive events, and digital engagement, the Ranchers are revolutionizing how fans experience pickleball. This includes using the latest in online social and AI community building tools and brand curation.   Investing in Players and Women's Sports – With top shot male players Christian Alshon and Michael Lloyd and women pros Etta Wright and Tina Pisnik–the team is leading the charge in offering diversity and equity in the team. The Ranchers are ensuring that female athletes have the same spotlight as the male counterparts.   Expanding Global Reach – With a focus on international expansion, the Ranchers are growing pickleball's footprint worldwide, attracting new fans, players, and markets.    Lil Wayne — co-owner of the Texas Ranchers MLP pickleball team drops his first official fan-gear collection. From $14 to $85, the line delivers bold, game-day style for any pickleball lover. Great stocking-stuffers, everyday wear, and court-ready accessories.   "I've always believed creativity doesn't belong to one lane. I love the opportunity to express what I can create beyond music. I hope everyone sees the Wayne in this collection. And, I hope people in the pickleball community see the Ranchers in it, too. Together, we're evolving the game and working to bring new audiences into it.  This collection represents that mindset." Lil Wayne    Shop the full collection at Lil Wayne Collection   Photos of Texas Ranchers MLPs and Texas Ranchers Juniors wearing collection         Show Notes:   SEGMENT 1 — Pickleball & League Structure History & Origins Pickleball began in 1965. Modern league landscape: Connor launched the PPA (Professional Pickleball Association) Steve Kuhn launched MLP (Major League Pickleball) PPA & MLP have since merged. League Format Team-based structure 23 teams total Roster: 2 men, 2 women, plus 2 reserves Premier level: 1 male + 1 female draft slot 7 teams in Challenger league Closed league → No relegation or promotion like European soccer. Season & Competition HQ in Austin 2025 season: May → September 25 matches, 3 points per win Playoffs: quarterfinals → semifinals → finals Teams spread across U.S.: Dallas, NY, Brooklyn, NJ, Chicago, 2 in CA, 2 in FL Operations Hybrid expense structure Auction-style draft Teams bid on players Player drops, trades 3-year rights retention Allowed to drop one player per year SEGMENT 2 — Media, Background, & Market Context Media Distribution Pickleball TV on Amazon Prime + YouTube Matches also aired on CBS and Fox Sports Guest Background Former athlete (soccer player), originally from Chicago Tech & e-commerce startup out of college → exited Worked in men's health publishing Later shifted to sports; settled in Austin, TX Austin Market Advantages Tech hub: Apple, Meta, Oracle HQ move UT Austin, Austin FC MLS team Strong tourism + events: F1, ACL, SXSW Pickleball court basics: smaller than tennis, includes the Kitchen Broader Vision Cultural momentum for pickleball Potential global expansion and Olympic inclusion someday SEGMENT 3 — Sports as an Asset Class & Permian Sports Investments Sports Ownership Trends Private equity now active in major leagues including the NFL $30 billion invested in pro sports in recent years Sports teams seen as assets—not just trophies—now more professionalized Permian Sports Investments Focused in Texas Operates as a holding company with investors (GP/LP structure) Vision: own & operate teams; expand into: NFL, NBA, MLB, NHL MLS and Formula One Goal: deliver equity appreciation + revitalize stale franchises Early-stage, but attracting celebrity & athlete investors Team facility: Austin Pickleball Ranch (2,000 seats) SEGMENT 4 — Sports, Real Estate & Stadium Economics Sports as an Economic Engine Stadiums attract traffic, dining, entertainment, tourism Sports = "event economy" → People come early, stay late (5–6 hours total) Stadium & District Development Vision to build 8–12k seat stadium Sponsorships Multi-purpose events to reduce costs Real estate opportunity similar to: Wrigleyville (Chicago) The Battery (Atlanta) → $65M/year revenue Sports Digital & Physical Ecosystem Districts support: Restaurants, hotels, rideshare Entertainment venues (TopGolf, theaters, event spaces) MLP Tour comes to Austin once per year 6 teams compete over a weekend Draws meaningful tourism traffic         If you enjoyed this show, you may like:   BRT Sports:  HERE   BRT Marketing: HERE   BRT Business: HERE   More - BRT Best of: https://brt-show.libsyn.com/category/Best+Of     Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ 'Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.    

À Bruxelles, les propriétaires qui louent leur logement via Airbnb sont dans le viseur du fisc. Une vaste opération de régularisation se prépare, avec à la clé plusieurs millions d’euros de recettes potentielles pour la Région. En Wallonie, le secteur des biotechnologies démontre une nouvelle fois sa résilience. Après la faillite d’Univercells, une partie de son savoir-faire renaît au sein d’une nouvelle société, Phoenix, soutenue par près de dix millions d’euros réinjectés par des investisseurs. Enfin, aux États-Unis, Donald Trump surprend en se posant en allié inattendu de l’industrie du cannabis. En plaidant pour sa reclassification comme substance moins addictive, le président américain pourrait favoriser l’essor économique du secteur. > Étude: Les préoccupations des CEO belges dépassent les enjeux nationaux Présentation: Ondine Werres Le Brief, le podcast matinal de L'Echo Ce que vous devez savoir avant de démarrer la journée, on vous le sert au creux de l’oreille, chaque matin, en 7 infos, dès 7h. Le Brief, un podcast éclairant, avec l’essentiel de l’info business, entreprendre, investir et politique. Signé L’Echo. Abonnez-vous sur votre plateforme d'écoute favorite Apple Podcast | Spotify | Podcast Addict l Castbox | Deezer | Google PodcastsSee omnystudio.com/listener for privacy information.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jennifer Sheller, SVP and Head of Global Clinical Trial Operations at Merck talks about simplifying trial protocols and what she likes about Merck's hybrid functional service provider model for conducting trials in over 60 countries. Jennifer shares her experiences integrating Merck's acquisitions without breaking studies or losing people, using new technology to improve trial operations, and co-designing studies with trial sites for agility and speed.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of Data in Biotech, Ross Katz sits down with Callie Celichowski and Isa Kupke from Veloxity Labs to discuss how their CRO leverages speed, precision, and innovation to support drug development. Learn how they use mass spectrometry, cloud-based infrastructure, and hands-on client partnerships to drive rapid, high-quality bioanalytical insights that support everything from preclinical studies to FDA submissions. What you'll learn in this episode: >> Why "speed with purpose" is essential for bioanalytical CROs supporting biotech and pharma clients >> The benefits and challenges of working with peptides and GLP-1 receptor agonists >> How the SCIEX 8600 enhances detection of low-concentration analytes Meet our guests Isa Kupke is Scientist II at Veloxity Labs, where she specializes in mass spectrometry and method development for preclinical and regulated bioanalytical programs. She also co-founded Blyde Botanics, bridging plant-based science and product development. Callie Celichowski is Senior Director of Business Development at Veloxity Labs, with over two decades in the pharmaceutical and CRO space. She's recognized for building strategic client partnerships and driving rapid, data-driven decision-making. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Isa Kupke on LinkedIn Connect with Callie Celichowski on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Returning guest Dean McAlister, EVP, Inizio Biotech, has spent over 35 years in Fortune 500 pharma leadership, including nearly 3 decades at AstraZeneca. Hear how to prepare to lead in an uncertain environment, how to develop conscious competence as a leadership skill, how to become more adaptable as a leader, how to stop your ego from getting in the way as a leader, and how to build the courage to say what needs to be said in meetings. Connect with Shirley at ShirleyKavanagh.com and on LinkedIn, and Dean on LinkedIn

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-evolving landscape of pharmaceuticals and biotechnology, a series of strategic transactions and scientific advancements are reshaping the industry.BioMarin's acquisition of Amicus Therapeutics for $4.8 billion is a significant highlight, marking the company's largest transaction to date. This move signifies a strategic pivot towards enhancing its capabilities in the rare disease sector, leveraging Amicus's expertise and robust pipeline to potentially improve patient outcomes in this highly specialized area. This acquisition is expected to enrich BioMarin's portfolio significantly with promising assets from Amicus, reflecting a strategic shift under new leadership towards rare disease treatments.Regulatory affairs have seen considerable activity as well, with the FDA raising concerns over manufacturing practices at Catalent's gene therapy facility. These issues, documented in a Form 483 following inspections, particularly pertain to the production of Elevidys. Such regulatory scrutiny emphasizes the critical importance of maintaining compliance with manufacturing standards in gene therapy—a burgeoning field within biotech that holds immense promise for treating genetically-driven conditions.The FDA's oversight extends beyond manufacturing practices to advertising, as evidenced by an untitled letter issued to Bristol Myers Squibb regarding their Cobenfy TV ad. This action is part of the FDA's broader initiative to ensure that direct-to-consumer marketing materials accurately portray drug benefits and risks, thereby protecting public health.In another strategic move, Alvotech and Teva are gearing up for the 2026 U.S. launch of an Eylea biosimilar following a settlement with Regeneron. This development highlights the competitive dynamics within the biosimilar market—a segment poised for growth as patents on major biologics expire, offering more cost-effective alternatives and expanding treatment access.Meanwhile, Clovis Oncology has achieved a milestone with Rubraca, which transitioned from accelerated approval to full FDA endorsement for prostate cancer treatment after five years. This progression underscores Rubraca's demonstrated efficacy and safety profile in addressing advanced prostate cancer—a notable achievement amid an increasingly competitive oncology market.Policy changes proposed by Health and Human Services Secretary Robert F. Kennedy Jr. could have profound implications by disrupting funding streams for hospitals providing gender-affirming care to minors. The potential impact on healthcare providers and patients who rely on these services is significant.Turning to clinical trials, Daiichi Sankyo has seen success with Enhertu receiving FDA approval for first-line HER2-positive breast cancer treatment. Nonetheless, challenges persist as a separate phase 3 trial for another antibody-drug conjugate was paused due to unexpected patient deaths. Meanwhile, Takeda plans to seek FDA approval for its TYK2 inhibitor following successful phase 3 trials in psoriasis—indicating promising potential in autoimmune disease therapies.Strategic shifts are evident across organizations as well, highlighted by Kathy Fernando's departure from Pfizer to join Replicate Bioscience as Chief Business Officer. Her new role focuses on advancing Replicate's self-replicating RNA technology platform—an area gaining traction due to its implications for vaccine development and therapeutic applications.On the clinical trials front, Altimmune reported encouraging results from a 48-week study on metabolic dysfunction-associated steatohepatitis (MASH). Their GLP-1/glucagon dual receptor agonist demonstrated sustained weight loss and improvements in non-invasive liver fibrosis measures—offering new hope for MASH patients who face limited treSupport the show

In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe sit down with Glafabra CEO: Dr. Chris Hopkins, geneticist, biochemist, and biotech entrepreneur, to explore the science and strategy behind next generation cell-based gene therapies for rare diseases.With more than 25 years of experience spanning gene augmentation, rare disease biology, CRISPR licensing, and biotech formation, Dr. Hopkins shares how autologous, ex vivo engineered cell therapies may overcome key limitations of current enzyme replacement and viral gene therapies, particularly for Fabry disease.The conversation dives deep into: • How lentiviral gene augmentation in patient derived cells enables sustained enzyme production • Why redosing matters and where one time AAV therapies fall short • The scientific rationale for early intervention, including potential newborn treatment • Differences between autologous and emerging allogeneic approaches • Regulatory pathways for rare disease therapies and recent FDA developments • The role of non animal models in translational research • Montana's early access therapy law and its broader implications • Building biotech platforms amid a challenging funding environmentTopics include cell based gene therapy, Fabry disease, lentiviral vectors, stem cell engineering, rare disease drug development, regulatory science, and translational medicine. Subscribe to BioTalk Unzipped for in depth conversations with the scientists and leaders shaping the future of biomedical innovation.00:00 - Intro00:53 – Welcome to BioTalk Unzipped, Guest intro: Dr. Chris Hopkins02:10 – Guest charity: Environmental Defense Fund03:12 – His journey into rare-disease therapeutics and Glafabra05:58 – Discovering a new enzyme-deficiency therapy 06:39 – Current standard of care 07:42 – How the new autologous cell therapy works09:40 – Treating patients earlier (even newborns)10:33 – Emerging therapies - AAV gene therapy vs. cell-based therapy12:16 – Long-term results & repeat dosing14:30 – Future plans: T-cells & allogeneic approaches18:08 – New News: FDA resubmission for rare disease20:00 – Navigating FDA pathways22:06 – Non-animal testing & alternative models25:50 – Montana's early-access therapy law & medical tourism29:03 – Could other states follow?31:31 – Biotech's current funding challenges33:46 – New News: Gene therapy trial saves 4-year-old37:09 – Long-term vision for expanding therapies39:53 – Personal segment: outdoor life & skiing44:43 – Guest question on international trade Dr. Christopher Hopkinshttps://www.linkedin.com/in/christopherehopkins/ Glafabra - https://www.glafabra.com/ Environmental Defense Fund - https://www.edf.org/ Dr. Chad Briscoe

As the global pharmaceutical industry enters a period of profound transition, this episode of Corner Office Conversation examines what lies ahead. Hosts Vikas Dandekar and Teena Thacker talk to Stefan Oelrich, Head of the Pharmaceuticals Division at Bayer AG, about the forces reshaping drug discovery and access from trade tensions and shifting innovation hubs to the promise and uncertainty of cell and gene therapies. Oelrich reflects on Europe’s struggle to stay competitive as capital and talent flow increasingly toward the US and China, and argues that meaningful reform will require faster regulation, leaner bureaucracy, and quicker patient access. He also addresses the looming loss of exclusivity for blockbuster drugs and outlines how Bayer plans to offset revenue impact with a packed pipeline of new launches. India emerges as both an opportunity and a test case, offering scale and growth while raising tough questions on affordability and access. At its core, the conversation asks whether breakthrough science can move fast enough to serve patients without losing public trust.You can follow Vikas Dandekar on his social media: X and Linkedin and read his Newspaper Articles.You can follow Teena Thacker on his social media: X and Linkedin and read her Newspaper Articles.Listen to Corner Office Conversation: Corner Office Conversation with Knight Frank’s William Beardmore-Gray and Shishir Baijal, Corner Office Conversation with Sridhar Vembu, CEO, of Zoho Corporation, Corner Office Conversation with Gunjan Soni, Country Managing Director, Youtube India, Corner Office Conversation with Elizabeth Reid, Head of Search, Google and much more. Catch the latest episode of “Corner Office Conversation” on: Spotify, Amazon Music, Apple Podcasts,and wherever you get your podcasts from.See omnystudio.com/listener for privacy information.

A Note from James:One of my favorite conversations on this show was with Peter Thiel. Yes—PayPal, Facebook, Palantir, and a dozen other hits. I first ran this episode years ago, and the advice still holds up. The same stories, the same frameworks—and the same challenge to think from first principles. Here's Peter Thiel, one of the most influential entrepreneurs of our time. Episode Description:In this redux, James pressure-tests the core ideas from Peter Thiel's Zero to One—why competition is for losers, how real monopolies are built, and why starting “narrow” is often the only path to something huge. They cover Facebook's early moat (real identity), PayPal's network-effect wedge on eBay, and the “10x or nothing” bar for proprietary technology. Peter shares a contrarian read on bubbles, why biotech's slump may be opportunity, and how to hire, divide roles, and keep teams from fighting. The through-line: seek secrets, combine disciplines, and make something so different that it becomes its own category. What You'll Learn:How to pick markets the Zero to One way: start with a “small, winnable monopoly,” then expand in concentric circles. The four classic moats—and which to favor first: proprietary tech, network effects, economies of scale, and brand (with a bias toward real tech). A practical rule for virality vs. network effects: growth is a tactic; enduring value comes from the network that forms once users arrive. Team design that prevents internal warfare: make roles uniquely owned; if two people own the same thing, you're paying for a fight. How to hunt “secrets”: believe they exist, look where consensus is stale, and borrow from adjacent fields to see what specialists miss. Timestamped Chapters:[02:00] A Note from James — Why this conversation still ranks among the best. [03:00] Zero to One, in one line — “Do something new, different, fresh, strange.” [05:17] Competition vs. Capitalism — Why perfect competition kills profits; aim for uniqueness. [07:28] Facebook's original edge — Real identity as the breakthrough vs. MySpace's alt-persona culture. [09:14] Bits vs. Atoms — Stagnation outside software and how biology could become an information science. [12:05] Personality and perseverance — Why mild contrarian wiring helps founders ignore status games. [15:21] “10x or nothing” — The technology and/or experience must be an order of magnitude better. [17:00] Monopoly thinking, ethically done — Create abundance by creating something truly new. [23:30] The PayPal pre-history — Why long-running trust among teammates births more companies. [30:10] Early Facebook investment logic — College-only looked “small,” which was exactly the point. [32:03] Turning down $1B — The boardroom debate, optionality, and founder conviction. [36:23] Moats in practice — Picking the right advantage (and why brand alone is shaky). [37:06] Network effects ≠ virality — How value compounds after growth. [39:54] PayPal's wedge — eBay power-sellers and the $10 incentive as a growth accelerant. [41:22] Beware the “Chinese refrigerator” TAM slide — Start small, win big. [42:01] Uber vs. Airbnb — Investor bias and why some models get over- or undervalued. [44:18] Bubbles and the public — What changes across tech, housing, and today's “government bubble.” [48:00] War on cash & credit — Why Peter favors unlevered, opaque innovation over fixed income. [51:10] Biotech headwinds (and upside) — Regulation, Eroom's Law, and why sentiment can misprice breakthroughs. [53:50] Secrets — If you assume they exist, you'll be the one to find them. [57:56] Interdisciplinary bets — CS × biology; CS × transportation; why university silos miss the action. [59:51] Silicon Valley on HBO — The “Peter Gregory” caricature and what the show gets right. Additional Resources:Zero to One: Notes on Startups, or How to Build the Future (book) — Amazon hardcover. AmazonFounders Fund — Peter Thiel profile (bio & portfolio highlights). Founders Fund“PayPal Mafia” overview (alumni companies: YouTube, Yelp, LinkedIn, Tesla, SpaceX, Palantir, Yammer). WikipediaYahoo's 2006 $1B offer for Facebook (background reporting). Business InsiderEroom's Law (pharma R&D productivity; Nature Reviews Drug Discovery). NatureSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Scott Wren of Wells Fargo Investment Institute on global strategy and positioning, plus Steve Liesman wraps his key interview with Fed Governor Christopher Waller. Apple's outlook with Craig Moffett of MoffettNathanson. The Goldman biotech outlook with Salveen Richter of Goldman Sachs. Next week's market catalysts with Adam Crisafulli of Vital Knowledge. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements, revealing a landscape rich with scientific innovation and strategic maneuvers poised to impact patient care and the drug development pipeline.Let's start with Johnson & Johnson's recent FDA approval for a subcutaneous version of Rybrevant, their lung cancer medication. This new formulation offers a more convenient administration method compared to AstraZeneca's Tagrisso, intensifying competition in the non-small cell lung cancer market. The shift towards more patient-friendly delivery systems underscores the industry's commitment to enhancing treatment adherence and convenience. In contrast, Insmed faced a setback with its phase 2 trial for Brinsupri in treating chronic rhinosinusitis without nasal polyps. The discontinuation of this program highlights the unpredictable nature of clinical trials and emphasizes the need for rigorous scientific validation before advancing therapeutic candidates.Meanwhile, Lilly has shown promising results with its oral obesity pill, marking significant progress in weight management therapies. Patients transitioning from injectable GLP-1 therapies to Lilly's oral drug candidate maintained substantial weight loss, positioning Lilly favorably against Novo Nordisk's Wegovy. The potential for oral formulations to revolutionize treatment paradigms in chronic conditions cannot be understated. Lilly's progress in obesity treatment with its oral medication orforglipron further cements its competitive edge. Participants in their Phase III clinical trial maintained weight loss after switching from Wegovy or Zepbound to orforglipron, suggesting an efficacious oral alternative to injectable treatments and potentially enhancing patient adherence.On the regulatory front, the Biosecure Act's progression within a major defense spending bill could impose new challenges for life sciences companies with Chinese affiliations. This legislative shift reflects geopolitical tensions impacting global pharmaceutical collaborations and underscores the importance of regulatory compliance in international partnerships. Similarly, Intercept Pharmaceuticals' restructuring following the withdrawal of Ocaliva from the U.S. market is indicative of strategic pivots in response to regulatory hurdles and evolving market dynamics.In dermatology, Takeda's successful phase 3 trials for Zasocitinib highlight the competitive nature of drug development as multiple players vie for market share within therapeutic areas. Their anticipated 2026 FDA filing underscores the prolonged timelines involved in bringing novel therapies to market despite successful clinical outcomes.Public-private collaborations continue to play a crucial role in vaccine development, as evidenced by Moderna's pandemic influenza vaccine advancement into phase 3 trials with support from the Coalition for Epidemic Preparedness Innovations (CEPI). This $54 million investment illustrates ongoing efforts to bolster pandemic preparedness through innovative mRNA technologies. Meanwhile, Moderna's $54 million funding from CEPI to advance its bird flu vaccine highlights resilience amidst fluctuating governmental support. This endeavor leverages Moderna's mRNA technology platform, emphasizing mRNA's versatility across various infectious diseases.Shifting our focus slightly, medical groups have expressed opposition to changes in hepatitis B vaccination recommendations by the CDC for newborns. Such policy debates have significant implications for public health strategies and highlight ongoing discussions within medical communities regarding optimal vaccination protocols.GSK's strategic collaboration with Camp4 Therapeutics marks another key industry development. With an investment exceeding $400 million, GSK aims to Support the show

Join us for an insightful episode of The Edge of Show as we dive into the world of decentralized AI finance with Ron Bodkin, co-founder and CEO of Theoriq Labs. With over 15 years of experience in applied AI, Ron shares his journey from working at tech giants like Google to pioneering a decentralized AI protocol that empowers autonomous agents to manage capital and execute strategies on-chain.In this episode, we explore:The intersection of AI and blockchain technologyThe importance of decentralization in the future of financeHow Theoriq Labs is leveraging AI agents to enhance DeFi strategiesThe challenges and opportunities in creating a decentralized ecosystemInsights into the future of capital markets and the role of AI agentsWhether you're a crypto enthusiast, a tech innovator, or just curious about the future of finance, this episode is packed with valuable insights and thought-provoking discussions.Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!Support us through our Sponsors! ☕

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Was tun, wenn eine E-Mail das ganze Leben verändern könnte? Dr. Philipp Baaske hat für sein Unternehmen ein Kaufangebot über mehrere hundert Millionen Euro erhalten. Ein Exit, der vieles ermöglichen würde. Und doch hat er das Angebot abgelehnt. In dieser Podcastfolge spreche ich mit dem Gründer von NanoTemper Technologies über diese Entscheidung und über das, was folgt, wenn man sich bewusst gegen das schnelle Geld entscheidet. Heute beschäftigt NanoTemper rund 240 Mitarbeitende an neun Standorten weltweit. Ihre biophysikalischen Messgeräte spielen eine zentrale Rolle in der Entwicklung von mRNA-Impfstoffen. Für seine Arbeit wurde Philipp Baaske mehrfach ausgezeichnet, unter anderem mit dem Deutschen Gründerpreis und dem Deutschen Innovationspreis. Seine Haltung hat er in seinem Buch „The Honorable Entrepreneur“ beschrieben. Unser Gespräch kreist um Fragen, die selten offen gestellt werden: um Verlockung und Verzicht, um Unabhängigkeit, Verantwortung und Vertrauen. Wir sprechen darüber, was Geld ermöglicht und was es nicht lösen kann. Über persönliche Prägungen, über ein starkes „Warum“ und über den Preis und die Chancen, die werteorientiertes Unternehmertum mit sich bringt. Im Gespräch geht es unter anderem um: - die bewusste Entscheidung gegen Venture Capital und für Kundenfinanzierung - die Verlockung des schnellen Geldes und ihre Wirkung auf Unternehmer - Führungskultur jenseits von Schlagworten - schnelles Wachstum, seine Risiken und Lernmomente - den Schritt vom operativen Co-CEO zum Executive Chairman Ein Gespräch über unternehmerische Verantwortung, über Vertrauen – und darüber, was Erfolg bedeuten kann, wenn man ihn nicht nur in Zahlen misst. Ihr findet Philipp auf LinkedIn unter: https://www.linkedin.com/in/philipp-baaske/ und auf seiner Website gibt es den Zugang zum Buch und zu weiteren Informationen: https://www.philippbaaske.com Alle Informationen zu meiner Arbeit findet ihr wie immer unter: www.hannah-panidis.de Und hier begegnet ihr mir meist tagesaktuell: Instagram: https://www.instagram.com/hannahpanidis LinkedIn: https://www.linkedin.com/in/hannah-panidis-55141a145/?originalSubdomain=de Facebook: https://www.facebook.com/HannahPanidisKommunikation/?locale=de_DE

In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, CEO at Zymeworks and Josh Smiley, president and COO at Zai Lab, about how renewed confidence is driving biotech entering 2026. As we look towards conversations that will shape this year's J.P. Morgan Healthcare Conference, the biotech industry is fueled by improving market sentiments, visible at recent meetings like Jeffries in London, and reinforced by a wave of partnerships, strategic acquisitions and Chinese collaboration that is recalibrating investor expectations.HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsKenneth Galbraith, CEO, ZymeworksJosh Smiley, President and Chief Operating Officer, Zai LabDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation, Josh Kriger is joined by Josh Lawler, Cathy Hackl, Nicholas Zaldastani, and Janet Adams as they unpack the global race toward artificial general intelligence (AGI) and why decentralization may be the key to building ethical, transparent, and inclusive AI systems.The discussion dives into agentic AI, decentralized infrastructure, trust networks, data ownership, deepfakes, humanoid robotics, and the growing risks of centralized control. From real-world AI governance challenges to the role blockchain can play in accountability and verification, this episode cuts through the hype and focuses on what actually needs to be built and fixed.If you're building, investing, or simply trying to understand where AI and Web3 are heading next, this conversation offers clear insights from leaders working at the edge of innovation.Watch now and join the conversation shaping the future of intelligence.Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕

Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really takes to build a biotech company that lasts. From Roivant's transformational $7B Pfizer-to-Roche deal to delivering registrational Phase 3 data in dermatomyositis—one of biotech's most difficult graveyard indications—Matt shares how disciplined execution, decentralization, and learning from failure shaped Roivant's trajectory. The discussion explores Roivant's unique “Vant” model, why multiple CEOs can outperform centralized command-and-control structures, and how thoughtful clinical trial design—down to steroid tapering and site execution—can make or break outcomes in rare disease development. Beyond science and strategy, Matt reflects candidly on his own evolution as CEO, the realities of leading a public biotech through volatile markets, and why authenticity, focus, and embracing hard lessons matter more than chasing hype. This episode is a masterclass in biotech leadership, clinical development, and long-term value creation. Biography: Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

How can universities become powerful engines of innovation, startups, and economic growth—especially in a challenging funding environment? In this episode, host Elaine Hamm, PhD, sits down with Kimberly Gramm, PhD, MBA, the David & Marion Mussafer Chief Innovation and Entrepreneurship Officer at the Tulane Innovation Institute and Managing Director of Tulane Ventures. Kimberly shares how Tulane is building a comprehensive innovation ecosystem—from early-stage programming and mentorship to venture funding—designed to help researchers, students, and founders translate discovery into real-world impact. Together, they explore what it takes to change institutional culture, scale innovation thoughtfully, and position universities as active investors in the future of biotech and healthcare. In this episode, you'll learn: How universities can support founders and technologies across every stage of the innovation journey, not just at commercialization. Why mentorship, alumni engagement, and listening to stakeholders are critical to building sustainable innovation programs. How strategic venture funds and proof-of-concept investments can accelerate biotech spinouts and regional economic growth. Whether you're a researcher, founder, or innovation leader, this episode offers a behind-the-scenes look at how universities can step up, take risks, and help innovation thrive—even in uncertain times. Links: Connect with Kimberly Gramm, PhD, MBA, and check out Tulane Innovation Institute and Tulane Ventures. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out our previous episode with Kimberly. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant updates that are shaping the future of healthcare, patient care, and drug development.The U.S. Food and Drug Administration has been particularly active recently, granting Johnson & Johnson a National Priority Review Voucher for its multiple myeloma drug combination. This move highlights the importance of J&J's treatment in addressing unmet needs within oncology, a field continuously striving for innovative solutions. These vouchers expedite the review process, reflecting a broader commitment to accelerating the availability of critical therapies for patients who need them most.Continuing with regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu, in combination with Roche's Perjeta, has gained FDA approval as a first-line treatment for unresectable or metastatic HER2-positive breast cancer. This breakthrough is supported by late-stage study results demonstrating a 44% reduction in disease progression or death compared to standard care. The approval signifies not only progress in breast cancer therapeutics but also underscores the potential benefits of strategic collaborations in drug development. Such partnerships are increasingly vital as they aim to optimize therapeutic efficacy through shared expertise and resources.In contrast to these advancements, Pfizer is facing financial recalibrations with projected revenues for 2026 estimated to decline due to diminishing COVID-19 vaccine sales and patent expirations. This situation reflects broader industry challenges as companies navigate post-pandemic market dynamics and patent cliffs, forcing reevaluations of long-term strategies.On another front, Gilead Sciences continues to push boundaries in HIV treatment with a promising single-tablet regimen combining bictegravir and lenacapavir. This innovation targets underserved segments within the HIV market, offering streamlined treatment options that could enhance patient adherence and outcomes significantly.Shifting focus to obesity management, Novo Nordisk's oral semaglutide is emerging as a highly anticipated medication among primary care providers. This trend highlights a growing preference for oral GLP-1 therapies as convenient alternatives to injectable formulations, marking a shift in how obesity—a major public health concern—is managed.The importance of regulatory compliance remains evident as Novo Nordisk received an FDA warning letter concerning manufacturing issues at an Indiana site previously owned by Catalent. This incident underscores the necessity for rigorous quality control in pharmaceutical manufacturing, which can have far-reaching implications on operational dynamics and supply chains.The FDA is also pioneering efforts to incorporate real-world evidence into medical device submissions by opening pathways for extensive deidentified datasets from sources like national cancer registries and electronic health records. This policy shift aims to integrate diverse data sources into the evidentiary foundation for medical device evaluations, potentially fostering innovation within this sector.In line with collaborative efforts, Genentech has partnered with Caris Life Sciences in a multi-year agreement valued at up to $1.1 billion, emphasizing the strategic importance of integrating diagnostic advancements with therapeutic developments to achieve precision medicine goals.Meanwhile, Yarrow Bioscience has acquired an autoimmune thyroid disease drug from China's Gensci, exemplifying a growing trend of cross-border collaborations aimed at leveraging global innovation ecosystems to address diverse therapeutic areas. This acquisition is part of a $1.37 billion deal, reinforcing the globalization of biotech partnerships as companies seek access to novel therapeutics andSupport the show

This week on Careers in Discovery, we're joined by Peter Hamley, Founder and CEO of Scripta Therapeutics.  Peter didn't follow the typical founder path. After a long and successful career in big pharma R&D and business development, he made the leap into Biotech with a mission: to unlock the potential of transcription factors in treating neurodegenerative diseases. What followed was a complete mindset shift - from structure and scale to agility and risk.  In this episode, Peter shares the thinking behind Scripta's unique approach to drug discovery, how his experience at Sanofi and AstraZeneca shaped his leadership style, and why failure, iteration, and clarity of purpose are more important now than ever. 

DescriptionWelcome to this episode of The Edge of Show, where we dive into the forces reshaping AI, Web3, and the future of digital trust. We're joined by Sandy Carter to break down the biggest shifts happening right now in AI, blockchain, and digital identity. We get into IBM's $11B Confluent acquisition, how AI agents are already making decisions inside major companies, and why stablecoins just surpassed Visa and Mastercard in global settlement volume.We also cover Sandy's predictions for 2026: the rise of autonomous agents, the trust layer blockchain provides, decentralized robots, and why every company will need real-time verification. Plus, Sandy gives us an inside look at what's next for Unstoppable Domains as identity moves fully on-chain.If you want a clear, no-nonsense breakdown of where the digital economy is actually heading, this episode is it.Tune in now and join the conversation!

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

India's cotton story was once a global success - yields tripled & exports surged. But over the last few years, India has gone from second largest exporter to net importer of cotton. ThePrint Editor-in-Chief Shekhar Gupta explains reasons behind India's tragic cotton collapse, and breaks down the data over the past few decades. #CutTheClutter Ep 1772----more----Read Harish Damodaran's article here: https://indianexpress.com/article/opinion/columns/why-india-fell-behind-in-the-cotton-race-an-aversion-to-science-and-technology-9912107/

What does it take to build a biotech company without burning billions—or losing your conviction? In this episode of CPO PLAYBOOK, Felicia Shakiba sits down with Dr. Shalabh Gupta, Founder & CEO of Unicycive Therapeutics, a physician-turned-Wall-Street-analyst who built and took a biotech company public in a way few ever do. Dr. Gupta shares how he raised $150M+ in public markets, went public with just one employee, and scaled to FDA submission readiness with only 22 people—all without relying on traditional Silicon Valley venture capital. This conversation unpacks what real CEO discipline looks like in one of the most unforgiving industries in the world—and what leaders in any industry can learn from it. You'll learn: • Why great CEOs start with the problem—not the product • How to scale a capital-intensive business with radical focus • Why FDA alignment is a leadership skill, not a regulatory hurdle • How public-market thinking changes founder decision-making • What investors actually look for in CEO credibility and trust Chapters 00:00 Introduction to Unisysive Therapeutics 04:27 Innovative Approach to Biotech 07:55 Understanding the Biotech Landscape 10:39 Transition from Medicine to Wall Street 14:08 Lessons from Genentech 19:46 Building a Company Alone 22:47 The Importance of Networking 27:00 Engaging with the FDA 30:57 Raising Capital in Biotech 41:58 Navigating Investor Relationships This episode is a masterclass in purpose-driven leadership, capital discipline, and building companies that last. — Subscribe to CPO PLAYBOOK for more conversations at the intersection of leadership, innovation, and capital strategy: https://www.cpoplaybook.com/newsletter Need support scaling leadership or culture? Let's talk: https://www.cpoplaybook.com/contact-us

What if we could predict how chemicals affect human lungs without using animals? In this episode of Sounds of Science, Mary McElroy, Head of Discovery Toxicology and Pharmacology at Charles River, joins us to explore a groundbreaking collaboration with MatTek Life Sciences. Together, they're pioneering human-relevant, non-animal models that could revolutionize inhalation toxicology. From 3D lung tissues to computational dosimetry, discover how science is catching its breath and moving toward a safer, more ethical future. Show NotesInhalation Toxicology | Charles River Mini Organs Offer Alternative Method for Predicting Drug Safety and Efficacy Alternative Methods Advancement Project | Charles River Charles River, in Collaboration with MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives 

Shares of Ford on the move after the automaker announced a $19.5b write off of its electric vehicle business. What the company is focusing on now, instead. Plus Terns Pharmaceuticals announced positive results for its new cancer drug last week. The CEO joins to lay out next steps for the company.  Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you've ever checked the ingredients on a baked good, you know how ubiquitous eggs are. They bind, they lift, they emulsify, they hold moisture — they're simply the structural engineers of cookies, cakes, and muffins everywhere. But they're also volatile: prices spike, supply chains break, and for anyone with an egg allergy or who's avoiding eggs for animal welfare or environmental reasons, eggs aren't exactly a welcome ingredient to find on the ingredient deck.  Enter Hadar Ekhoiz Razmovich, CEO and co-founder of Meala FoodTech, an Israeli startup that's figured out how to make peas do what eggs and hydrocolloids do, and has consequently raised several million dollars in venture capital so far. Meala's breakthrough lies in taking simple pea protein and using advanced biotechnology to unlock its hidden abilities — creating a single-ingredient powder that they say can whip, bind, and gel just like an egg in baked goods and alternative meat. No multi-ingredient formulations, no methylcellulose, no animal inputs — just plants doing some biochemical magic.  In this episode, Hadar shares how her background in R&D led her to tackle one of food science's toughest challenges: replacing eggs and hydrocolloids without sacrificing texture, taste, or cost. We talk about how Meala's technology works, what it takes to convince industrial bakeries to swap eggs for peas, and why she believes clean-label ingredients like this are the future of food.  Hadar is not just rethinking what we eat, she and her team are rebuilding the food system from scratch, one cookie, cake, and croissant at a time.  Discussed in this episode  Meals is backed by The Kitchen Food Tech Hub, DSM's venture arm, Milk & Honey Ventures, Lasenor, and EIT.  Our past episode with Milk & Honey Ventures' Beni Nofech.  More on Meala's egg replacer, GroundBaker, is here.  You can see two pending patent applications of Meala's here and here.    Get to know Hadar Ekhoiz Razmovich  Hadar Ekhoiz Razmovich brings over 12 years of leadership experience in the global food industry, with a strong focus on driving innovation and R&D across traditional food sectors. Throughout her career, she has led complex, multidisciplinary projects from early concept development to full commercial launch, consistently bridging technological capabilities with real market needs.  In 2021, she founded Meala FoodTech with a mission to transform the food industry. Under her leadership, Meala is pioneering clean-label functional protein that deliver superior texture, bite, and mouthfeel—without compromise and without undesirable additives. Her work empowers food manufacturers to create simpler, more natural, and better-tasting products, setting a new benchmark for next-generation of food.  Hadar is widely recognized for her strategic vision, deep industry insight, and ability to translate scientific innovation into scalable commercial solutions. 

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path. Bruce discusses his experiences as a first-time CEO at ProKidney, a late-stage autologous cell therapy biotech focused on pioneering new treatments for chronic kidney disease (CKD), the benefits of FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, how delaying or avoiding kidney dialysis would be a game-changer for CKD patients, and more.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of Data in Biotech, host Ross Katz sits down with Eshani Galermo, Staff Scientist at SCIEX, to explore the next generation of mass spectrometry in pharma and biopharma. Eshani explains how innovations like the ZenoTOF 8600 are redefining sensitivity, selectivity, and workflow efficiency in bioanalytical chemistry. Discover how high-resolution accurate mass (HRAM) systems are unlocking new capabilities in drug discovery, clinical studies, and regulatory science. What you'll learn in this episode: >> Why traditional mass spectrometry falls short in modern bioanalysis >> How the ZenoTOF 8600 enhances sensitivity and reduces sample volume needs >> The role of high-resolution systems in detecting complex drug metabolites >> How automation tools are streamlining workflows for bioanalytical scientists >> The complementary role of AI and ML in mass spec data analysis Meet our guest Eshani Galermo is a Staff Scientist at SCIEX, where she leads global strategic marketing initiatives for pharma and biopharma quant applications. With deep expertise in bioanalytical chemistry and mass spectrometry, she has held multiple scientific roles across SCIEX, Emery Pharma, and Genentech.  About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Eshani Galermo on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Welcome to this episode of The Edge of Show, where we dive into the forces reshaping AI, Web3, and the future of digital trust. We're joined by Sandy Carter to break down the biggest shifts happening right now in AI, blockchain, and digital identity. We get into IBM's $11B Confluent acquisition, how AI agents are already making decisions inside major companies, and why stablecoins just surpassed Visa and Mastercard in global settlement volume.We also cover Sandy's predictions for 2026: the rise of autonomous agents, the trust layer blockchain provides, decentralized robots, and why every company will need real-time verification. Plus, Sandy gives us an inside look at what's next for Unstoppable Domains as identity moves fully on-chain.If you want a clear, no-nonsense breakdown of where the digital economy is actually heading, this episode is it.Tune in now and join the conversation!

Networking in biotech doesn't have to feel awkward or transactional. In this episode, Carina shares how giving first is the simplest way to build authentic biotech networking on LinkedIn that actually leads to stronger relationships and better opportunities.If you're an introvert, early-career professional, or making a career change, this is your practical roadmap to connect with confidence.In this episode, you'll learn:Why “give first” makes networking feel easier (and work better)How to add value even if you're early in your career or switching fieldsWhat to say when you feel you've got nothing to offerThe biggest outreach mistakes that make messages feel transactionalSimple LinkedIn actions that build visibility and trust over timeInsights from the Biotech Career Coach community's December networking challenge (and what drove major reach growth)Want support, templates, and challenges to stay consistent?✅ Join the Biotech Career Coach Skool community to connect with peers, access templates, and take part in challenges to grow your LinkedIn presence and your biotech network.Learn more about the Collaboratory Career Hub community and access our free resources:Join our Skool CommunityTake the Free 7-day Interview Sprint ChallengeCheck out our sister podcast: Building BiotechsSend Carina a connection request on LinkedIn!Stay connected with us:

“Drug development has become slower and more expensive despite all the new technology,” says Eric Hughes, executive vice president of Global R&D and chief medical officer of Teva Pharmaceutical. “That’s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we’re in a unique position where we can stay really hyper-focused on what we’re doing. I’m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they’re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva’s doing right.” In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.See omnystudio.com/listener for privacy information.

Join us for an insightful episode of The Edge of Show as we dive into the world of decentralized AI finance with Ron Bodkin, co-founder and CEO of Theoriq Labs. With over 15 years of experience in applied AI, Ron shares his journey from working at tech giants like Google to pioneering a decentralized AI protocol that empowers autonomous agents to manage capital and execute strategies on-chain.In this episode, we explore:The intersection of AI and blockchain technologyThe importance of decentralization in the future of financeHow Theoriq Labs is leveraging AI agents to enhance DeFi strategiesThe challenges and opportunities in creating a decentralized ecosystemInsights into the future of capital markets and the role of AI agentsWhether you're a crypto enthusiast, a tech innovator, or just curious about the future of finance, this episode is packed with valuable insights and thought-provoking discussions.Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕

Lab-made eggs. Lab-made sperm.Children engineered, screened, and selected.Marriage optional. Mothers and fathers optional.Embryos discarded like products.IVG: the new horror of Bio-Tech

Synopsis: This episode is proudly sponsored by Quartzy. What happens when engineering discipline, business pragmatism, and breakthrough immunology collide? In this episode of Biotech 2050, host Alok Tayi sits down with Jay Hartenbach, President & COO of Diakonos Oncology, to unpack one of the most unconventional—and promising—approaches in cancer immunotherapy today. Jay traces his journey from biomedical engineering into biotech operations, sharing how Diakonos was built outside the traditional venture playbook and why the company chose to tackle two of the most punishing cancers first: glioblastoma and pancreatic cancer. He reveals how Diakonos' dual-loading dendritic cell platform creates an exponentially stronger immune response—essentially tricking the body into launching a viral-level attack against cancer. From capital-efficient clinical execution to nontraditional fundraising and early signs of durable patient responses, this conversation offers a rare, behind-the-scenes look at how bold science, disciplined operations, and relentless persistence can reshape what's possible in oncology. Biography: Jay Hartenbach is a distinguished leader in the biotechnology and wellness sectors, known for his passionate commitment to advancing innovative healthcare solutions and transforming patient outcomes. He currently serves as President and Chief Operating Officer at Diakonos Oncology, where he is leading the team through the development and clinical advancement of pioneering immunotherapies targeting some of the most difficult-to-treat cancers, including glioblastoma and pancreatic ductal adenocarcinoma.​ Since joining Diakonos Oncology, Jay has been instrumental in achieving significant milestones such as attaining FDA Fast Track and Orphan Drug Designation for the company's lead candidate, DOC1021, securing greater than $30 million in financing, and establishing research collaborations with leading cancer centers to advance the clinical trials of the company's novel dendritic cell vaccine platform. Before his role at Diakonos, Jay co-founded Medterra, a globally recognized wellness company that set industry standards for quality and innovation, and where he continues to serve as Chairman of the Board, shaping high-level strategic direction. He also co-founded Perland Pharmaceuticals, an early-stage biotech firm focused on developing therapies for arthritis conditions, and has held leadership and board advisory roles across several life sciences ventures.​ Jay holds a degree in biomedical engineering from the University of Miami and a Master of Engineering Management from Duke University, grounding his entrepreneurial leadership with scientific expertise.

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go in the year. On the latest BioCentury This Week, BioCentury's analysts discuss the rise in large M&A deals and what the trends among the 37 acquisitions say about biopharma dealmaking.The analysts assess first-in-human in vivo CAR T data at the American Society of Hematology meeting from Kelonia Therapeutics, which showcase the promise of the modality and justify the growing pipeline. They also break down readouts from Praxis in developmental and epileptic encephalopathy from the American Epilepsy Society Annual Meeting and from Novo Nordisk, which presented full data at the Clinical Trials on Alzheimer's Disease meeting on semaglutide's failure to treat Alzheimer's disease.Washington Editor Steve Usdin analyzes a roller-coaster week at FDA in which Richard Pazdur resigned as director of FDA's Center for Drug Evaluation and Research and Tracy Beth Høeg became acting CDER director, a move that Usdin says will prompt staff departures, ease restraints on FDA leadersView full story: https://www.biocentury.com/article/657781#BiotechMA #CARTTherapy #EpilepsyResearch #AlzheimersDisease #FDA02:37 - Biotech M&A06:39 - In vivo CAR T10:08 - Semaglutide for Alzheimer's16:17 - Praxis22:11 - FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies. Sean also discusses FDA pathways, incentives, and agency engagement, and offers thoughts on the regulatory outlook for cell and gene therapies.     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

This episode dives into the fascinating intersection of biotech, AI, and automation with Mr. Guru Singh, CEO/Founder of Scispot and Y Combinator alumnus. Learn how a data-driven, autonomous lab future is taking shape.Could labs run by AI agents and robots cure cancer and revolutionize manufacturing within a decade, and what role does critical thinking play in the AI era?✅ The Digital Brain of the Lab: Discover how Scispot is building an operating layer to connect siloed data, turning life science labs into autonomous, data-driven research centers.

Welcome to this episode of The Edge of Show, where we dive deep into the world of Web3, blockchain, and the future of finance! Join us with our special guest BrendanSedo from Core as they explore hot topics including:The impact of large public companies like Strategy Inc. holding massive Bitcoin treasuries and the risks involved.Texas became the first U.S. state to officially buy Bitcoin for its treasury, signaling a shift in government sentiment towards crypto.The evolution of neobanks into self-custodial financial apps, blurring the lines between traditional banking and decentralized finance.An in-depth look at CoreDAO, a high-performance Layer 1 blockchain designed to extend Bitcoin into DeFi and DApps, including exciting updates on their new liquid staking token.Whether you're a crypto enthusiast, a fintech professional, or just curious about the future of money, this episode is packed with insights and analysis that you won't want to miss!Tune in now and join the conversation!

Welcome to this episode of The Edge of Show, your gateway to the Web3 revolution! In this episode we sit down with Dr. Mohamed Omer Ali, the founder of EazyBot, and Winston Thomas, the Global Sales Director of EazyBot. Together, they explore the transformative world of cryptocurrency, automation, and trading strategies.Episode Highlights:Discover the inspiration behind EazyBot and how it aims to empower users in the crypto space.Learn about Dr. Ali's journey from engineering to crypto and the pivotal moments that led to the creation of EazyBot.Understand the importance of safety in trading and how EazyBot ensures users maintain custody of their assets.Hear insights on the current state of the crypto market, including Bitcoin's volatility and the significance of diversification in trading strategies.Get a sneak peek into upcoming features and partnerships for EazyBot, including new exchanges and a mobile app.Whether you're a seasoned trader or just starting your crypto journey, this episode is packed with valuable insights and practical advice. Join us as we navigate the future of finance and technology!Support us through our Sponsors! ☕